HUMANIGEN INC (HGEN)

US4448632038 - Common Stock

0.0361  -0.16 (-81.12%)

After market: 0.0358 0 (-0.83%)

News Image
4 months ago - InvestorPlace

HGEN Stock Alert: Why Humanigen Just Filed for Ch. 11 Bankruptcy

Humanigen stock is falling hard on Friday as investors in HGEN sell shares after the company announced a bankruptcy filing.

News Image
9 months ago - Newsfile

Humanigen Announces First Participant Dosed in RATinG Trial of Lenzilumab for Early Treatment of Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation

The RATinG (Risk Adapted Therapy in Acute GvHD) is the first trial to explore granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralization for...

News Image
10 months ago - InvestorPlace

Biogen Layoffs 2023: What to Know About the Latest BIIB Job Cuts

Biogen (BIIB) layoffs are on the way as the company seeks further profits with its upcoming Alzheimer's disease drug launch.

News Image
10 months ago - InvestorPlace

Why Is Bellerophon Therapeutics (BLPH) Stock Down 34% Today?

Bellerophon Therapeutics (BLPH) stock is losing value on Tuesday after the clinical-stage therapeutics company was sent a delisting notice.

News Image
10 months ago - InvestorPlace

Why Is Humanigen (HGEN) Stock Down 72% Today?

Humanigen (HGEN) stock is falling hard on Tuesday after the company warned investors it can't keep listing requirements.

News Image
10 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time for another dive into the biggest pre-market stock movers as we check out the most recent news for Tuesday morning!

News Image
10 months ago - Seeking Alpha

Humanigen stock falls on bankruptcy plan and delisting

Nano-cap biotech Humanigen (HGEN) fell ~70% pre-market Tuesday after announcing that Nasdaq has decided to delist its shares from the exchange and the company is evaluating all...

News Image
a year ago - Newsfile

Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress

Of the 14 participants enrolled and treated with lenzilumab plus azacitidine, ten are evaluable with three to eighteen months of...

News Image
a year ago - Newsfile

Humanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of Leukemia

CMML is an aggressive, poorly understood cancer; approximately 20% of patients survive three years from diagnosisEleven subjects dosed with lenzilumab...

News Image
a year ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We're starting off another day of trading with a breakdown of the biggest pre-market stock movers for trader need to kno about Wednesday!

News Image
a year ago - SBWire

NASDAQ: HGEN Long Term Investor Alert: Investigation over Potential Wrongdoing at Humanigen, Inc.

San Diego, CA -- (SBWIRE) -- 12/15/2022 -- An investigation was announced for current long-term investors in shares of Humanigen, Inc. (NASDAQ: HGEN) concerning potential breaches of fiduciary duties by certain directors of Humanigen, Inc.

News Image
1 years ago - Newsfile

Humanigen Reports Third Quarter 2022 Financial Results

Short Hills, New Jersey--(Newsfile Corp. - November 14, 2022) - Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused...

News Image
1 years ago - Newsfile

Humanigen Announces Participation and Presentation at Jefferies London Healthcare Conference

Short Hills, New Jersey--(Newsfile Corp. - November 10, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused...